MXPA03001227A - Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados. - Google Patents
Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados.Info
- Publication number
- MXPA03001227A MXPA03001227A MXPA03001227A MXPA03001227A MXPA03001227A MX PA03001227 A MXPA03001227 A MX PA03001227A MX PA03001227 A MXPA03001227 A MX PA03001227A MX PA03001227 A MXPA03001227 A MX PA03001227A MX PA03001227 A MXPA03001227 A MX PA03001227A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- pyridinamine
- cell death
- related methods
- provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Esta invencion provee composiciones farmaceuticas neuroprotectoras que comprenden 2-piridinaminas; esta invencion tambien provee metodos para utilizar estas composiciones para evitar muerte celular isquemica, particularmente muerte celular neuronal, y deducir la probabilidad de muerte celular neuronal en un sujeto debido a un evento traumatico; finalmente esta invencion provee un aparato para administrar a un sujeto las composiciones farmaceuticas de la presente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22379500P | 2000-08-08 | 2000-08-08 | |
PCT/US2001/041565 WO2002011724A2 (en) | 2000-08-08 | 2001-08-06 | Neuroprotective 2-pyridinamine compositions and related methods |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03001227A true MXPA03001227A (es) | 2004-09-10 |
Family
ID=22837998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03001227A MXPA03001227A (es) | 2000-08-08 | 2001-08-06 | Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados. |
Country Status (13)
Country | Link |
---|---|
US (2) | US20020198219A1 (es) |
EP (1) | EP1317266A2 (es) |
JP (1) | JP2004510707A (es) |
CN (1) | CN1635890A (es) |
AR (1) | AR030140A1 (es) |
AU (1) | AU2001278206A1 (es) |
BR (1) | BR0113148A (es) |
CA (1) | CA2418912A1 (es) |
IL (1) | IL154267A0 (es) |
MX (1) | MXPA03001227A (es) |
NZ (1) | NZ524101A (es) |
WO (1) | WO2002011724A2 (es) |
ZA (1) | ZA200301861B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6811992B1 (en) * | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
WO2002060492A1 (en) * | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
BRPI0417354A (pt) * | 2003-12-03 | 2007-03-13 | Cytopia Res Pty Ltd | compostos inibidores de tubulina, composições e seus usos |
NZ571203A (en) | 2006-03-31 | 2011-12-22 | Novartis Ag | Monocyclic heteroaryl-phenyl-cyclohexyl compounds for treating diseases mediated by DGAT-1 activity |
GB0606774D0 (en) * | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
WO2008128968A1 (en) * | 2007-04-19 | 2008-10-30 | Novartis Ag | Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5 |
GB0821307D0 (en) * | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
JPWO2013081094A1 (ja) * | 2011-11-30 | 2015-04-27 | 東レ株式会社 | イミダゾ[1,2−a]ピリジン誘導体及びその医薬用途 |
US9079866B2 (en) | 2013-02-04 | 2015-07-14 | Janssen Pharmaceutica Nv | Flap modulators |
TWI644899B (zh) | 2013-02-04 | 2018-12-21 | 健生藥品公司 | Flap調節劑 |
AU2018243691B2 (en) * | 2017-03-27 | 2022-05-12 | Cardurion Pharmaceuticals, Llc | Heterocyclic compound |
GB201809102D0 (en) * | 2018-06-04 | 2018-07-18 | Univ Oxford Innovation Ltd | Compounds |
KR20210082454A (ko) | 2018-09-25 | 2021-07-05 | 카듀리온 파마슈티칼스, 인크. | 아미노피리미딘 화합물 |
CA3196946A1 (en) | 2020-09-28 | 2022-03-31 | Cardurion Pharmaceuticals, Inc. | Fused heteroaryl compounds and their use as camkii inhibitors |
EP4366724A2 (en) * | 2021-07-09 | 2024-05-15 | CZ Biohub SF, LLC | Cdk19-selective inhibitors, and methods of use thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0000816A1 (en) * | 1977-08-06 | 1979-02-21 | Beecham Group Plc | Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them |
US5506231A (en) * | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
US5519035A (en) * | 1993-07-02 | 1996-05-21 | Cornell Research Foundation, Inc. | Treatment of stroke or in anticipation of the occurrence of brain ischemia |
US5536718A (en) * | 1995-01-17 | 1996-07-16 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
KR0138353Y1 (ko) * | 1996-12-13 | 1999-04-01 | 주식회사부윤테크 | 일회용 주사기 |
EP0949242A4 (en) * | 1996-12-24 | 2004-09-08 | Chugai Seiyakukabushiki Kaisha | AROMATIC AMINE DERIVATIVES HAVING AN INHIBITORY ACTION WITH RESPECT TO OUR |
US6200993B1 (en) * | 1999-05-05 | 2001-03-13 | Merck Frosst Canada & Co. | Heterosubstituted pyridine derivatives as PDE4 inhibitors |
US6316474B1 (en) * | 1999-10-29 | 2001-11-13 | Merck & Co., Inc. | 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists |
EP1261327B1 (en) * | 2000-02-25 | 2005-04-27 | F.Hoffmann-La Roche Ag | Adenosine receptor modulators |
-
2001
- 2001-08-06 EP EP01956179A patent/EP1317266A2/en not_active Withdrawn
- 2001-08-06 AU AU2001278206A patent/AU2001278206A1/en not_active Abandoned
- 2001-08-06 IL IL15426701A patent/IL154267A0/xx unknown
- 2001-08-06 WO PCT/US2001/041565 patent/WO2002011724A2/en not_active Application Discontinuation
- 2001-08-06 NZ NZ524101A patent/NZ524101A/en not_active Application Discontinuation
- 2001-08-06 US US09/922,658 patent/US20020198219A1/en not_active Abandoned
- 2001-08-06 MX MXPA03001227A patent/MXPA03001227A/es unknown
- 2001-08-06 CA CA002418912A patent/CA2418912A1/en not_active Abandoned
- 2001-08-06 JP JP2002517060A patent/JP2004510707A/ja active Pending
- 2001-08-06 CN CNA018166911A patent/CN1635890A/zh active Pending
- 2001-08-06 BR BR0113148-6A patent/BR0113148A/pt not_active IP Right Cessation
- 2001-08-08 AR ARP010103804A patent/AR030140A1/es unknown
-
2003
- 2003-03-06 ZA ZA200301861A patent/ZA200301861B/en unknown
- 2003-03-28 US US10/402,094 patent/US20030225085A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR030140A1 (es) | 2003-08-13 |
BR0113148A (pt) | 2003-07-08 |
ZA200301861B (en) | 2004-07-07 |
US20030225085A1 (en) | 2003-12-04 |
JP2004510707A (ja) | 2004-04-08 |
WO2002011724A3 (en) | 2002-08-15 |
CA2418912A1 (en) | 2002-02-14 |
CN1635890A (zh) | 2005-07-06 |
EP1317266A2 (en) | 2003-06-11 |
NZ524101A (en) | 2004-11-26 |
WO2002011724A2 (en) | 2002-02-14 |
AU2001278206A1 (en) | 2002-02-18 |
US20020198219A1 (en) | 2002-12-26 |
IL154267A0 (en) | 2003-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03001227A (es) | Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados. | |
MY125978A (en) | Admantane derivatives | |
MY135683A (en) | Compositions for improving fertility | |
AU2003280087A1 (en) | Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton | |
DK0703786T3 (da) | Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS | |
NO993520D0 (no) | Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon | |
AP2003002755A0 (en) | Guanidinobenzamides as mc4-r agonists | |
NO20024586D0 (no) | Metode og preparater for å forhindre hormoninduserte bivirkninger | |
MXPA03001226A (es) | Derivados de 4-pirimidinamina, composiciones farmaceuticas y metodos relacionados. | |
EP1259240B8 (en) | Agents, such as nicotinamide or cadpr for the treatment of skin disorders | |
GB2352395A (en) | Paroxetine methanesulfonate | |
EP1391200A4 (en) | DRUG | |
MXPA03005340A (es) | Nuevas composiciones de medicamentos a base de anticolinergicos y ciclesonida. | |
AU2002236647A1 (en) | Method and device for administering medication and/or placebo | |
DE60128912D1 (en) | Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika | |
GB0002336D0 (en) | Medicaments | |
DE69923336D1 (de) | Oral anzuwendende buprenorphinhaltige arzneimittel | |
ZA200308221B (en) | Pharmaceutical compositions for oral and topical administration. | |
ZA200208761B (en) | Pharmaceutical form of administration for peptides, methods for its production and use. | |
TN2009000119A1 (en) | Combination drug | |
WO2002072021A3 (en) | Agents and methods for the prevention of initial onset and recurrence of existing cancers | |
IL166596A0 (en) | Salt of morphine-6-glucoronide | |
MXPA03001455A (es) | Compuestos de pirazol, composiciones farmaceuticas y metodos para modular o inhibir la actividad del amiloide-beta-peptido asociado a reticulo endoplasmico y l-3-hidroxiacil-coa-deshidrogenasa. | |
IL153540A0 (en) | THE USE OF 7beta-HYDROXY-STEROID DERIVATIVES FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS | |
EP1583545A4 (en) | PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF PEPTIDES OF HIV GP41 AND ITS THERAPEUTIC USE |